Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 9/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25357127 | 1.00 | TPH1 (0.60) | TPH1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL25356472 | 1.00 | TPH1 (0.60) | TPH1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL31303988 | 1.00 | TPH1 (0.60) | TPH1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL25356476 | 1.00 | TPH1 (0.60) | TPH1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL31370046 | 0.89 | CYP11B1 (0.52) | TPH1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL27122562 | 0.87 | NPC1 (0.63) | TPH1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL26966050 | 0.87 | NPC1 (0.63) | TPH1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL31523921 | 0.87 | NPC1 (0.63) | TPH1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL31688759 | 0.86 | GRIA2 (0.65) | TPH1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL12273163 | 0.85 | SLC7A5 (0.54) | TPH1SLC7A5ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PEPTIDREAM INC. (JP) | 2025-11-27 | — | — | US | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4541805-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PeptiDream Inc. (JP) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024252336-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | PEPTIDREAM INC. (JP) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2023243120-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | ペプチドリーム株式会社 | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | BMP4, BMP1, BMPR2 | TPH1 4441/4885SLC7A5 2541/4885ALPI 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.